NEW BLOOD TEST IDENTIFIES LUNG CANCER YEARS EARLIER THAN MOST ADVANCED IMAGING TECHNIQUES

Today, 20/20 GeneSystems, Inc. ("20/20") announced study results that show that its multi-biomarker blood test may be able to detect non-small cell lung cancer (NSCLC) significantly earlier and with better accuracy than CT scans, the most advanced technique in current use for detecting this disease. If the reliability of the test can be confirmed on larger numbers of patient samples, the company will seek to introduce what would be the first new blood screen for any cancer since the prostate-specific antigen (PSA) test was introduced in the 1970s. Study findings were published in today's Journal of Thoracic Oncology.
Genetic Engineering News